Compare Incyte Corporation (INCY) vs MINISO Group Holding Ltd (MNSO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs MINISO Group Holding Ltd — how do they compare? Incyte Corporation trades at $120.77 (market cap $24.54B), while MINISO Group Holding Ltd trades at $12.11 (market cap $3.62B). The key difference: Incyte Corporation is far larger — about 6.8× MINISO Group Holding Ltd's market cap, and MINISO Group Holding Ltd pays a 5.53% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | MNSO | |
|---|---|---|
Market Cap | $24.54B | $3.62B |
Sector | Health | Technology |
52-Week High | $129.93 | $26.63 |
52-Week Low | $81.66 | $11.30 |
Enterprise Value | $20.04B | $4.29B |
Dividend Yield | — | 5.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
MNSO trades at $11.9, down 4.95% in the last session, with technical indicators showing a neutral to bearish bias. Recent earnings show volatility, with a Q1 2026 beat but prior misses, while fundamentals reveal solid revenue growth and improving profitability. The company announced a HK$2 billion share repurchase program in June 2026, signaling confidence.
The outlook is mixed: strong analyst buy ratings (75%) and undervalued metrics like a P/E of 12.16 support upside, but recent price declines and competitive pressures pose risks. Earnings consistency and margin sustainability are key for investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →
